APRIL 20258EUROPEA Strategic Approach at EngelhardIn the fast-evolving life sciences sector, organizations face mounting pressures to reduce time-to-market, optimize costs, and improve the quality of their research and development efforts. A solution gaining significant traction is the use of Contract Research Organizations (CROs). Their ability to provide specialized expertise, streamline operations, and mitigate risks has made them central to the success of drug development programs. At Engelhard Arzneimittel, a German midsize pharmaceutical company, we partner with CROs to focus internal resources on core capabilities while staying agile and ensuring high standards of quality and compliance.This article summarizes insights from our experience, detailing how we've leveraged CRO partnerships to optimize drug development, the challenges we've encountered, and how these partnerships are evolving to meet the future demands of the life sciences industry.The Strategic Importance of CROs in Life SciencesTraditionally, CROs were seen as service providers for specific tasks like clinical trials or regulatory submissions. Today, they are integral to the strategic success of life sciences companies. The complexity of developing new therapeutics makes it increasingly difficult for in-house teams to manage all aspects. Consequently, the CRO industry has grown, offering specialized services that provide flexibility and speed - critical factors in today's competitive landscape.CROs allow companies to tap into a wealth of expertise, infrastructure, and cutting-edge technology without the need to invest in these capabilities internally. Some specialize in data handling, while others focus on specific therapeutic areas, such as OTC products, pediatrics, or oncology. This diversity enables companies to scale operations quickly, without the need for hiring and training additional staff.How Engelhard Optimized Drug Development Through CRO PartnershipsThrough years of collaboration with CROs, we have refined our approach to maximize their contributions across the drug development pipeline. Here are the key areas where CRO partnerships have made a tangible difference:1. Streamlining Preclinical ResearchBy outsourcing toxicology studies, pharmacokinetic evaluations, and bioanalytical testing, we significantly shortened timelines. These CROs brought deep expertise in preclinical testing, allowing us to focus on refining drug candidates rather than spending time on resource-intensive research.2. Optimizing Clinical TrialsClinical trials are one of the most complex and resource-heavy stages of drug development. By leveraging CROs, we accessed a broad network of clinical sites, accelerating recruitment and reducing data collection time. CROs also provided professional monitoring and project management teams, helping us streamline the process and ensure regulatory compliance.A key benefit was their ability to navigate diverse regulatory environments. As we expanded into global markets, their regulatory expertise ensured our trials met the By Yuliya Ilieva, Head of Clinical Research, EngelhardHARNESSING THE POTENTIAL OF CROSIN MY OPINION
< Page 7 | Page 9 >